Brent Neidig Sells 5,002 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Brent Neidig sold 5,002 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

USANA Health Sciences Trading Up 4.1%

Shares of NYSE:USNA traded up $0.76 on Thursday, reaching $19.16. 39,164 shares of the company traded hands, compared to its average volume of 123,440. The business’s 50-day simple moving average is $18.72 and its 200 day simple moving average is $19.42. USANA Health Sciences, Inc. has a 52 week low of $16.60 and a 52 week high of $38.32. The stock has a market capitalization of $353.62 million, a P/E ratio of 40.81, a price-to-earnings-growth ratio of 0.75 and a beta of 0.76.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The company had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Sell-side analysts expect that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on USNA shares. Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Finally, Zacks Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, USANA Health Sciences has an average rating of “Reduce”.

Institutional Trading of USANA Health Sciences

Several hedge funds have recently bought and sold shares of the stock. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 1.2% during the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after buying an additional 14,328 shares in the last quarter. Renaissance Technologies LLC raised its position in USANA Health Sciences by 1.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after purchasing an additional 21,793 shares during the period. Vanguard Group Inc. raised its position in USANA Health Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after purchasing an additional 57,249 shares during the period. Dimensional Fund Advisors LP raised its position in USANA Health Sciences by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after purchasing an additional 17,318 shares during the period. Finally, Nantahala Capital Management LLC purchased a new position in shares of USANA Health Sciences in the 4th quarter worth approximately $11,485,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.